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ABSTRACT
Background. Craniofacial dysmorphic features are morphological changes of the face
and skull which are associated with syndromic conditions. Moyamoya angiopathy is
a rare cerebral vasculopathy that can be divided into Moyamoya syndrome, which is
associated or secondary to other diseases, and into idiopathicMoyamoya disease. Facial
dysmorphism has been described in rare genetic syndromes with associatedMoyamoya
syndrome. However, a direct relationship between idiopathic Moyamoya disease with
dysmorphic facial changes is not known yet.
Methods. Landmarks were manually placed on frontal photographs of the face of 45
patients with bilateral Moyamoya disease and 50 matched controls. After procrustes
alignment of landmarks a multivariate, penalized logistic regression (elastic-net) was
performed on geometric features derived from landmark data to classify patients against
controls. Classifiers were visualized in importance plots that colorcode importance of
geometric locations for the classification decision.
Results. The classification accuracy for discriminating the total patient group from
controls was 82.3% (P-value = 6.3×10−11, binomial test, a-priori chance 50.2%) for
an elastic-net classifier. Importance plots show that differences around the eyes and
forehead were responsible for the discrimination. Subgroup analysis corrected for body
mass index confirmed a similar result.
Discussion. Results suggest that there is a resemblance in faces of Caucasian patients
with idiopathic Moyamoya disease and that there is a difference to matched controls.
Replication of findings is necessary as it is difficult to control all residual confounding
in study designs such as ours. If our results would be replicated in a larger cohort,
this would be helpful for pathophysiological interpretation and early detection of the
disease.
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INTRODUCTION
Craniofacial dysmorphic features are morphological changes of the face and skull which are
associated with syndromic conditions. Distinct characteristic values of individual faces can
be assigned to certain constellations of dysmorphic features typical or even pathognomonic
for some diseases. For clinical diagnosis the constellation of dysmorphic features is crucial
and often allows visual diagnosis. Dysmorphic features of the face and skull are typical in
Cornelia de Lange syndrome, Williams-Beuren syndrome and fragile X syndrome (Winter,
1996). In scientific literature some genetic syndromes are described in which a Moyamoya
phenomenon is accompanied with typical morphological abnormalities of the face (Bakri
et al., 1999; Taskintuna et al., 2003; Heyer et al., 2006; Girirajan et al., 2007;Miskinyte et al.,
2011; Kilic et al., 2012).
Moyamoya angiopathy is a rare vasculopathy characterized by bilateral progressive
narrowing and occlusion of the intracranial portion of the internal carotid artery, the
middle cerebral artery and the anterior cerebral artery (Guey et al., 2015). Epidemiological
data do not exist in Europe.Mainmanifestations in childhood or early adulthood are strokes
or cerebral bleedings. Often earlier transient ischemic attacks, headaches or choreatiform
movements are not recognized as severe warning symptoms before disabling manifestation
(Kraemer et al., 2012a; Kraemer et al., 2016; Kraemer et al., 2017). This ‘‘orphan disease’’ is
more often recognized in Asians, especially in Japan and Korea. However, it also appears
in Caucasians. In Europe and the USA it is very rare, epidemiology data are not known.
Per the definition, Moyamoya disease (MMD) is the term for bilateral disease without any
other manifestation former thought being idiopathic (Fukui, 1997; Bersano et al., 2016). In
contrast to this, Moyamoya syndrome (MMS) is associated with other diseases or states
like neurofibromatosis type 1, trisomy 21, vasculitis or states after skull radiation (Fukui,
1997; Guey et al., 2015).
The above mentioned association of facial dysmorphisms are only described in
MMS, especially in genetic syndromes (Guey et al., 2015) like trisomy 21, loss of BRCC3
deubiquitinating enzyme (Miskinyte et al., 2011), Smith-Magenis syndrome (Girirajan et
al., 2007), PHACE(S) syndrome (Heyer et al., 2006), Majewski osteodysplastic primordial
dwarfism type II (MOPD II) (Kilic et al., 2012), Seckel syndrome (Rahme et al., 2010) and
Alagille syndrome (Rocha et al., 2012). Facial dysmorphism associated with MMS seems to
be caused by the syndromes MMS is associated with (such as Smith-Magenis syndrome
Girirajan et al., 2007) and not part of the MMS spectrum.
A direct relationship between idiopathic Moyamoya disease with dysmorphic facial
changes is not known yet. The only study which assumes to an association between
Moyamoya disease and cephalocephalic parameters is from Qureshi et al. (2014). In
Quereshi’s study 13 patientswho are named as havingMoyamoya disease are comparedwith
39matched controls (Qureshi et al., 2014). This working group found a significantly greater
bi-parietal diameter, a significantly greater fronto-occipital diameter and a shorter distance
between bregma and occiput in Moyamoya disease patients compared with controls.
However, it has to be criticized that those patients with angiographically confirmed
Moyamoya angiopathy were defined as idiopathic Moyamoya disease just in absence of
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trisomy 21. No other clinical data like CSF data or exclusion of NF1 or other genetic
syndromes were found in this article.
Thus, this study was intended to clarify if also in those patients with Moyamoya disease
thought to be idiopathic due to detailed exclusion of differential diagnoses distinctive facial
features could be found. Detecting any typical distinctive facial features also in MMD and
not only in rare genetic syndromes with MMS would allow potential pathophysiologic
conclusions and would enable physician to recognize this rare disease earlier.
MATERIALS AND METHODS
The study was approved by the local ethics committee (no.: 03-2357) and informed
written consent was obtained from all patients. A total of 45 individuals with MMD
diagnosed as idiopathic participated in this study. All patients were examined via MRI
and conventional angiography. Adult patients with bilateral idiopathic MMD listed in
the database of the Moyamoya outpatient clinic at the Alfried-Krupp Hospital in Essen,
Germany were considered for the present study. The patients met the diagnostic criteria of
the ‘‘Research Committee on Spontaneous occlusion of the Circle ofWillis’’ of the Japanese
Ministry of Health (Fukui, 1997). Patients with Moyamoya syndrome were excluded.
Moyamoya syndrome was diagnosed in patients with the following conditions or diseases:
after cerebral radiotherapy, cerebral vasculitis, atherosclerosis, Down syndrome and
Neurofibromatosis 1. Moreover, exclusion criteria included known concomitant diseases
defining Moyamoya syndrome associated with facial abnormality such as MOPD II. All
patients earlier underwent detailed examinations including transesophageal sonography,
CSF, serum studies and skin examination to exclude other known reasons for MMS.
The patients were contacted per phone or email. For the acquisition of the photos
instructions were sent to patients on how to take photos by themselves and sent in
photos were checked for quality. We list the instructions in the appendix. In further cases
photos were taken in the hospital on regular consultation (Alfried Krupp Hospital, Essen,
Germany).
The patient group was matched with the control group on basic demographic variables
such as age, gender and ethnicity. Controls were recruited from an earlier study and gave
informed consent for the use of their facial data in studies concerning syndromic facial
traits. The instructions for photography was the same like in patients as listed in the
appendix.
The Essen cohort was described earlier (Boehringer et al., 2011b).
In addition, controls were also recruited through announcements in public places such as
public offices, local labor, and citizen offices. In total 50 caucasian controls were recruited.
The mean age was 42.16 (median 41, SD 13.92) years. Nine male and 36 female patients
were enrolled. All patients and controls were comparable in age and gender (see Table 1).
All had Caucasian family background and came from central Europe mainly Germany.
Clinical features of the patients are described in Table 2.
Landmarking of all facial photographs was performed manually by a single rater (QBH).
A graph containing 31 landmarks was used and is shown in Fig. 1. Both patients and
controls were of Caucasian family background.
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Table 1 Demographic characteristics of study participants.
Patients (n= 45) Controlls (n= 50)
Males 9 11
Females 36 39
Age (mean) 42.16 42.06
Age (median) 41 41
Age (standard deviation) 13.92 14.33
Table 2 Clinical features.
Clinical feature Percent of patients affected
Symptom: transient ischemic attack 60%
Symptom: stroke 73%
Symptom: headaches 31%
Symptom: cerebral bleeding 6%
Livedo racemosa 11%
Arterial hypertension 36%
As discussed below, confounding may play an important role in this study. To control
for possible confounding due to high BMI, which might influence apparent resemblance
of the face and might be more prevalent in the MMD group, a subgroup analysis was done.
To this end, a subset of patients with BMI lower than 25 was compared to controls.
Statistical analysis
We used methods described previously to analyze the data (Boehringer et al., 2011a;
Balliu et al., 2014; Günther et al., 2015). In short, landmarks were manually placed on
frontal photographs of patients and controls. A procrustes analysis was performed to
align landmarks across photographs and a multivariate, penalized logistic regression was
performed to classify patients against controls. Regressions were computed using elastic
net regression as implemented in the R package glmnet. Penalization was necessary due
to the high number of predictor variables (Trevor Hastie & Friedman, 2009). We used
elastic net regression that allows to estimate models when there are more predictors
than observations and simultaneously selects predictors, i.e. omits variables not necessary
for prediction (Trevor Hastie & Friedman, 2009). Predictor variables were computed as
follows: Input features for this regression were based on transformations of the landmark
coordinates. First, 2D-coordinates were used as resulting from the Procrustes analysis.
Secondly, pairwise distances between all landmarks were computed. Third, a Delaunay
triangulation of the landmarks was computed and areas of the resulting triangles were
computed. Fourth, angles within all these triangles were computed. Finally, all these values
were combined in a vector being used as predicting variables in the penalized regression.
The graph used contained 31 nodes and resulted in 62 coordinates, 741 pairwise distances,
47 areas, and 141 angles, resulting in a total of 991 features per photograph. An example
(the author QBH) is shown in Fig. 1.
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Figure 1 This example graph shows the author (QBH) with the Landmarks used in the study. In con-
trast to the author, all patients and controls were of Caucasian family background.
Full-size DOI: 10.7717/peerj.4740/fig-1
Classification accuracy was calculated using cross-validation and classifiers were
visualized using importance plots. Importance plots are a color-coded representation
of classifiers where for each point in the image the color represents how important features
close to this point are for the classification decision. The value used for the color is computed
by weighting absolute regression coefficient of a feature with the inverse of the distance of
the feature to the point and summing up these values across all features to produce a single
value per point. Finally, average images of the group were superimposed with these color
representations (Balliu et al., 2014). Details of the procedures can be found in the cited
literature (Boehringer et al., 2011a).
To increase reliability, the same rater (QBH) has done landmarking of the face photos for
a second time to compare the results. We compared landmarks coordinates of the control
group between the two batches with the same penalized regression. The classifier could
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Table 3 Number of selected features per category.
Coordinate Distance Area Angle
All 1 49 4 22
Low BMI 11 84 15 51
distinguish the two batches almost perfectly (accuracy 98%) indicating high intra-rater
variability. Classification was based on 27 features, which is less than the number of
features found in classifiers for the Moyamoya phenotype (76 and 161). The P-value for
the classification accuracy is a binomial test comparing observed with a-priori accuracy. It
was calculated using R version 3.1.3 using function binom.test and a one-sided alternative.
RESULTS
Averages of the patient and control groups are shown in Fig. 2. Averages for the total patient
group and low BMI patient group seem very subtle. In addition, patient and control group
look very similar.
The classification accuracy for discriminating the total patient group from controls
was 82.3% (P-value = 6.3 ×10−11, binomial test, a-priori chance 50.2%) for a mixing-
parameter of 0.05 for the elastic-net classifier. A total of 76 features were selected to achieve
the discrimination (Table 3). The importance plots show that differences around the
eyes and forehead were responsible for the discrimination. Changes in angles seem to
dominate the discrimination as the pattern exhibited by angles dominates the importance
plot combining all features (Fig. 3).
The classification accuracy for discriminating the low BMI patients from controls
was 83.9% (P-value = 2.4 ×10−10, binomial test, a-priori chance 51.5%). Again, the
mixing-parameter for the elastic-net classifier was 0.05 for the best model with 162 selected
features (Table 3). The importance plots are very similar to the ones for discriminating the
total patient group from controls.
DISCUSSION
The pathophysiology of MMD remains unclear and is still a matter of controversy (Bersano
et al., 2016). Nevertheless, the final common pathway seems to involve proliferation of
smooth muscle cells and their migration from media to intima. This process is regulated
by various growth factors (Bersano et al., 2016). Elevated levels of basic fibroblast growth
factors, soluble adhesionmolecules, cellular retinoic acid-binding protein I, and hepatocyte
growth factor were found (Bersano et al., 2016). Apoptosis, as reported to be associated with
elevated caspase-3, occurred in themedia of theMCAofMMDpatients (Takagi et al., 2006).
Pathophysiologically, the pathways in the cell cycle are of particular interest, notably the
DNAmaintenance and the DNA damage response/repair (DDR) (Achrol et al., 2009; Sigdel
et al., 2013). The above mentioned Xq28 deletion in three families with MMS result in loss
of BRCC3, which is described to entail a defective angiogenesis in zebrafish (Miskinyte et
al., 2011). Pericentin mutations in Seckel disease and MOPD II, both systemic diseases
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Figure 2 Average images of all Moyamoya patients (A) and all controls (B). Average images of patients
(C) and controls (D) with low BMI.
Full-size DOI: 10.7717/peerj.4740/fig-2
associated with MMS, also argue for a crucial role of the DNA damage repair system in
the pathophysiology of MMA (Sigdel et al., 2013). Radiation as a trigger for MMS does
also underline this as a possible pathophysiological mechanism (Sigdel et al., 2013). It is
reasonable to assume that these pathophysiological mechanisms might also play a role in
the observed changes in faces.
The role of the RNF213 mutation in MMD is still unclear. In Asia, in 95% of familiar
and 79% of sporadic MMD the RNF213mutation p.R4810K could be detected as a founder
mutation. In contrast to this, in Caucasians no similar major founder gene seems to exist.
Nevertheless, there are hints for genetic contributing factors also in Caucasian patients
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Figure 3 Importance plots, visualizing the classifiers. (A) All features, all patients; (B) all features, low
BMI; (C) coordinates, all patients; (D) coordinates, low BMI; (E) distances, all patients; (F) distances, low
BMI; (G) areas, all patients; (H) areas, low BMI; (I) angles, all patients; (J) angles, low BMI.
Full-size DOI: 10.7717/peerj.4740/fig-3
(Shoemaker et al., 2015). The Caucasian cohort in total may be more heterogeneous than
the Asian cohort. However, it remains unclear how this type of genotype could affect the
mechanism of craniofacial dysmorphism.
Given the rare occurrence in Caucasians, it has been controversially discussed, if analyses
of these collectives should include all patients with MMA (e.g., MMD, MMS and unilateral
type of MMA) or should be restricted to patients with idiopathic bilateral MMD only
(Kraemer et al., 2012b) and some studies show inaccurate terminology (Kraemer et al.,
2012b). In general, incidence and prevalence data in Japan are restricted to idiopathic
bilateral MMD exclusive of MMS, while those in Europe and in the US are often reported
inclusing MMA and unilateral MMA (Kraemer, Heienbrok & Berlit, 2008). The strength of
this study was to include only those patients in whom idiopathic etiology was established
due to the established criteria (Fukui, 1997). Moreover, our cohort size of 45 patients with
MMD compared with the cohort sizes in the former Asian studies seems to be adequate
considering that MMD is a rare disease in Europe (Kraemer, Heienbrok & Berlit, 2008).
Results suggest that there is a resemblance in faces of Caucasian patients with idiopathic
Moyamoya disease and that there is a difference to matched controls.
Facial appearance seems to be almost identical between the groups. Flipping forth
and back between images reveals that they are not identical but differences are subtle.
Statistically, importance plots help to pinpoint the differences as found by the classifier.
Angles of the triangle (21-41-43), which contains the nasion, seem to most influence the
classifier by noticing that the contribution of all features (Figs. 3A, 3B, all) most resembles
the contribution of angles (Figs. 3I, 3J, angles).
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However, results as outlined for classification results and the underlying importance plots
need to be interpreted with caution. Although photograph acquisition was standardized by
a protocol, it is impossible to control all possible confounding factors such as lighting, or
subtle pose deviations (Vollmar et al., 2008; Boehringer et al., 2011a). An important caveat
is that patient and controls were recruited at different time points. Manual labeling was
performed in a short time window of one week to avoid systematic changes in landmark
evaluation. Apart from the variables above, camera technology, photographer, and more
could potentially lead to confounding. Ideally, patients and controls would be matched
on all important confounders, such as age, sex, and BMI and photographs would be taken
on each pair in a single session. This ideal situation could not be achieved. However, by
standardizing photograph acquisition, second landmarking, investigating the influence
of BMI, and relying on a single rater, we tried to control variability in the study. Our
re-labeling experiment indicates that intra-rater labeling can exceed true effects. However,
this re-labeling experiment was conducted more than a year after the initial labeling
run, which easily allows for subtle re-interpretations of landmark positions. Also, the
features that caused the differences between the coordinate sets was different from the set
found for disease classification and relied on fewer features. Although we cannot exclude
classification purely based on labeling errors, we believe that our results support a subtle
but distinguishable phenotype. On the other hand, we expect that the classifiers developed
here would perform worse on unseen individuals as compared to the study internal results
(Boehringer et al., 2011a).
In conclusion, facial differences from a control population might be detectable in
idiopathic MMD using statistical means. If this results could be replicated in a larger
cohort this would be helpful for pathophysiological interpretation and early detection
of the disease. However, it is hypothesized that the differences in facial characteristics
compared with controls are clinically very subtle in Caucasian patients with MMD due to
genetic heterogeneity. In contrast to Asian patients, in Caucasians MMD it is thought to
be triggered by various genetic causes, which could or could not be associated with facial
abnormalities.
CONCLUSION
In conclusion, this study suggest that there is a resemblance in faces of Caucasian patients
with idiopathic Moyamoya disease and that there is a difference to matched controls.
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